AI synthesis of seven filings for Colgate-Palmolive Company
Amounts are in US dollars. Colgate-Palmolive reports on a calendar fiscal year; its most recent annual report covers the fiscal year ended December 31, 2025, and the latest quarterly report covers the quarter ended September 30, 2026.
Business
From the FY2025 Form 10-K, accession 0000021665-26-000006.
Colgate-Palmolive sells everyday consumer staples, toothpaste, toothbrushes, mouthwash, soaps, shower gels, deodorants, skin care, dishwashing liquids, household cleaners, fabric conditioners, and specialty pet food, in more than 200 countries and territories. In 2025, Oral Care made up 44% of worldwide net sales, Personal Care 17%, Home Care 16% and Hill's Pet Nutrition 23%. About two-thirds of net sales come from outside the United States, and roughly 45% from emerging markets. Its customers are retailers, wholesalers and distributors; Pet Nutrition goes through authorized pet supply retailers, veterinarians and eCommerce. Walmart and its affiliates bought about 11% of 2025 net sales, and no other customer reached 10%.
It reports two product segments:
- Oral, Personal and Home Care. Colgate leads the world in toothpaste (41.3% global share for full-year 2025) and manual toothbrushes (32.4%), and it leads in liquid hand soap. Its brands include Colgate, Darlie, elmex, hello, meridol, Sorriso and Tom's of Maine in oral care; Palmolive, Protex, Softsoap, Irish Spring, Sanex, Speed Stick and Lady Speed Stick in personal care; EltaMD, Filorga and PCA SKIN in skin health; and Ajax, Axion, Fabuloso, Murphy, Suavitel and Soupline in home care. Oral Care also sells pharmaceutical products to dentists and other oral health professionals. Oral Care is a substantial part of the Asia Pacific business.
- Hill's Pet Nutrition. This segment sells specialty dog and cat food in over 80 countries under Hill's Science Diet (everyday nutrition, sold as Science Plan in Europe), Hill's Prescription Diet (therapeutic foods) and Prime100, a fresh pet food brand in Australia. Prime100 came with the April 30, 2025 purchase of Care TopCo Pty Ltd for AU$471 million (about $301 million).
The consumer products segment is run through regional reportable operating segments. In the 10-K there were five: North America, Latin America, Europe, Asia Pacific and Africa/Eurasia. The structure changed for 2026. Starting with the quarter ended March 31, 2026, Europe and Africa/Eurasia (excluding Russia and Belarus) were combined with the skin health business, which had been in North America, to form a new Europe, Middle East & Africa (EMEA) segment. Russia and Belarus moved into Asia Pacific. That leaves four regional segments, North America, Latin America, EMEA and Asia Pacific, alongside Hill's Pet Nutrition. The company recast its historical segment information onto the new basis in a Form 8-K filed March 17, 2026 (accession 0000021665-26-000010). Consolidated results did not change.
Corporate costs sit outside the segments: overhead, research and development ($366 million in 2025), stock-based compensation, restructuring charges and gains or losses on sales of non-core product lines. At year-end 2025 the company had about 33,600 employees in more than 100 countries, over 84% of them outside the United States. It operates about 325 owned or leased properties. Its main research and development centers are in New Jersey (oral and personal care), Mexico (home care) and Kansas (pet nutrition), and it runs shared service centers in India, Mexico and Poland.
Strategy. The company finished its 2025 strategic plan and now runs a 2030 strategy built on five priorities: using the reach of its brands, science-based innovation, "omni-channel demand generation" across retail, eCommerce and social media, data, analytics and AI capabilities, and its internal culture. Two cost programs pay for it. One is an ongoing "funding-the-growth" program that cuts material, logistics and overhead costs. The other is the Strategic Growth and Productivity Program, approved July 31, 2025, which realigns the organization and supply chain. When the 10-K was filed, that program was expected to cost $200 to $300 million pre-tax in total. It was expanded in April 2026 (see Current quarter).
Risk factors
From the FY2025 Form 10-K, accession 0000021665-26-000006. The Q3 2026 Form 10-Q (accession 0000021665-26-000048) reports no material changes to these risk factors.
- International exposure and currency. About two-thirds of sales originate outside the US. That exposes Colgate to exchange-rate swings, which shrink the dollar value of foreign profits and raise local supply costs. It also exposes the company to exchange controls, limits on getting cash home, price and profit controls, and possible expropriation. Hyper-inflationary economies, including Argentina, Nigeria and Türkiye, make currency volatility worse. Colgate offsets this with price increases, sourcing and selective hedging, and it warns these measures have not always been enough.
- Geopolitics, wars and trade. Russia and Ukraine: Eurasia was about 1% of 2025 net sales and about 2% of operating profit. Colgate has no factories in Russia but has trouble getting cash out of the country and finding banking services there. Venezuela: the company still has a factory there, but local results have been excluded from the consolidated statements since December 31, 2015. US tariffs following the 2025 executive orders, retaliation by trading partners, and renegotiation of the USMCA have added to input costs and hurt consumer sentiment. The 10-Q adds a further risk: the Middle East conflict, including between the United States and Iran, has raised shipping costs and the prices of oil, resin and agricultural inputs.
- Input-cost volatility. Resins, essential and tropical oils, pulp, tallow, corn, poultry and soybeans are all subject to price swings. In 2025, higher raw and packaging material costs cut 420 basis points from gross margin. Price increases used to offset costs can reduce volume or push shoppers to private label, and Colgate hedges commodities only to a limited extent.
- Competition and a shifting retail landscape. Colgate competes with multinationals, local players, private label and new direct-to-consumer entrants that eCommerce, social commerce and AI have made easier. Large retailers have more bargaining power and exclusive first-party consumer data. They demand trade discounts, slotting fees, retail media spending and changes to assortment. Retailers consolidating would concentrate the risk further.
- Innovation and reputation. Growth depends on launching differentiated products and getting regulatory approvals, including from the FDA. Negative publicity about ingredients, packaging, sourcing or AI-generated content on social media could damage the brands, and counterfeits are a further brand threat.
- Acquisitions, divestitures and impairment. Acquired businesses can disappoint. In Q4 2025 the skin health business, mainly Filorga, triggered a non-cash charge of $794 million after tax ($919 million pre-tax) after weaker category growth and performance, particularly in China.
- Supply chain and shared-service concentration. Some materials come from single or few suppliers. Finance, IT, customer service and logistics are concentrated in a handful of key office facilities.
- Cost programs may under-deliver. Funding-the-growth savings and the Strategic Growth and Productivity Program may come in late or short of plan. Parts of the restructuring require negotiation with works councils and unions.
- Cybersecurity and IT. Colgate depends on internal and third-party IT/OT systems, including cloud providers. The company has had cyber and data incidents, none with a material impact so far. The 10-Q notes an enterprise IT upgrade and move to the cloud now under way.
- Regulation of ingredients. Regulators are increasingly reviewing fluoride, titanium dioxide, synthetic colors and PFAS. Restrictions could force reformulation and hurt reputation. Anti-bribery, sanctions and trade-control rules also apply across a large international footprint.
- Litigation, especially talc. Colgate is a defendant in suits alleging that its historic talcum powder products contained asbestos or caused cancer. The 10-K describes talc litigation outcomes across the industry as ranging from dismissals to outsized compensatory and punitive jury awards (see Current quarter for the case count).
- Macro, credit and tax. Economic downturns push consumers toward cheaper products, and disruptions in the credit markets or a rating change could raise funding costs. On tax, the OECD Pillar II minimum tax and the January 2026 "Side-by-Side Package" are still being worked through. The IRS has also proposed imputing income on activities of one international operation. The 10-K puts the tax plus interest at about $165 million for 2010–2018; the 10-Q puts it at about $170 million for 2010–2021. Colgate believes the assessment is without merit, and the amount is not included in its uncertain tax positions.
Management's discussion, fiscal 2025
From the FY2025 Form 10-K, accession 0000021665-26-000006, with recast segment data from the Form 8-K filed March 17, 2026, accession 0000021665-26-000010.
Headline results. Net sales rose 1.4% to $20,382 million. Net selling prices added 2.1%, volume subtracted 0.4% and foreign exchange 0.3%; the Prime100 acquisition added 0.3% to volume. Organic sales, which exclude currency, acquisitions and divestments (a non-GAAP measure), also grew 1.4%. Hill's results were held back by lower private label pet food sales, which cut 320 basis points from that segment's organic growth. In its Q4 2025 earnings release (Form 8-K, accession 0000021665-26-000003), Colgate said it is exiting the private label pet food business.
Margins. Gross margin slipped to 60.1% from 60.5% (60.6% excluding 2024 restructuring charges). Material costs took off 420 basis points, partly offset by funding-the-growth savings (260 bps), pricing (80 bps) and mix (30 bps). Advertising was $2,703 million, 13.3% of sales. GAAP operating profit fell 23% to $3,306 million because of the $919 million pre-tax skin health impairment, a $99 million ERISA litigation charge, restructuring and acquisition costs. Excluding those items, operating profit was essentially flat at $4,347 million against $4,353 million, with margin down 40 bps to 21.3%. The impairment wrote down the Filorga trademark by $244 million and customer relationships by $93 million, and took a $582 million goodwill charge that left $51 million of skin health goodwill.
Earnings. GAAP net income attributable to Colgate fell to $2,132 million, or $2.63 per diluted share, from $2,889 million ($3.51). The effective tax rate was 26.1%. Excluding the items above, net income rose 1% to $2,996 million and diluted EPS rose 3% to $3.69 from $3.60.
Segments, as filed in the 10-K (old five-region basis):
- North America: net sales down 1.6% to $4,045 million; organic sales down 1.6% on weaker skin health, body wash, underarm protection and hand dish. Operating profit down 7% to $784 million.
- Latin America: net sales down 0.1% to $4,776 million after 4.0% negative currency; organic up 3.9%, led by Mexico, Argentina and Brazil. Operating profit down 8% to $1,411 million as material costs cut gross margin by 760 bps.
- Europe: net sales up 6.9% to $2,962 million; organic up 2.6%. Operating profit up 14% to $748 million.
- Asia Pacific: net sales down 1.5% to $2,814 million; organic down 1.0% on Greater China and India. Operating profit down 6% to $760 million.
- Africa/Eurasia: net sales up 7.0% to $1,172 million; organic up 6.5%, led by Türkiye and North Africa/Middle East. Operating profit up 1% to $255 million.
- Hill's Pet Nutrition: net sales up 2.9% to $4,613 million; organic up 1.2%. Operating profit up 10% to $1,064 million, with margin up 160 bps to 23.1%.
The same 2025 year on the new four-region basis. The March 2026 recast gives:
- North America: $3,679 million net sales and $790 million operating profit.
- Latin America: $4,776 million and $1,411 million.
- EMEA: $4,276 million and $938 million.
- Asia Pacific: $3,038 million and $820 million.
Hill's and the Corporate line ($1,717 million loss) are unchanged. 2026 segment figures should be compared with these recast amounts, not with the 10-K segment table above.
Cash and capital. Operating cash flow rose 2% to a record $4,198 million, and capital expenditures were $564 million. Dividends paid totalled $1,823 million ($2.06 per share), and share repurchases cost $1,210 million. Total debt was $7,988 million and cash $1,288 million at year-end. In 2025 the company issued $500 million of 4.20% five-year notes in April and €600 million of 3.25% ten-year notes in November. A $5 billion buyback authorization (the "2025 Program") replaced the prior program in March 2025. The $3 billion revolving credit facility now runs to November 2030.
Current quarter, Q3 2026
From the Q3 2026 Form 10-Q, accession 0000021665-26-000048, and the earnings release furnished on Form 8-K, accession 0000021665-26-000047 (both October 30, 2026). Q1 and Q2 2026 organic growth rates come from the earnings releases on Form 8-K, accessions 0000021665-26-000022 (May 1) and 0000021665-26-000041 (July 31). Segment figures are on the new four-region basis, with 2025 comparisons recast.
Growth picked up in Q3. Net sales rose 4.6% to $5,369 million on 1.7% volume growth, 2.0% net pricing and a 1.0% currency benefit. Organic sales grew 3.6%, faster than the 2.9% in Q1 and 2.4% in Q2 2026. The figure includes a 20 bp drag from the shrinking private label pet food business. Management described Q3 as its fourth straight quarter of sequential improvement in worldwide volume growth. Year to date, toothpaste share was 41.4% (up 0.3 points) and manual toothbrush share 33.1% (up 0.8 points).
Margin and reinvestment. Gross margin rose 80 bps to 60.2% (60.3% excluding restructuring). Funding-the-growth savings (290 bps), pricing (80 bps) and mix (20 bps) more than covered material cost inflation of 300 bps. Advertising absorbed most of that gain, rising 15% to $775 million, or 14.4% of sales against 13.1%. Excluding restructuring, operating profit rose 5% to $1,117 million, but margin improved only 20 bps to 20.8%. On a GAAP basis, which includes $30 million of pre-tax restructuring charges, operating profit grew 3% to $1,088 million while margin dipped 30 bps to 20.3%. Diluted EPS was $0.94 against $0.91. Excluding restructuring it was $0.97, up 7%.
Q3 by segment (net sales; organic growth; operating profit):
- North America: $905 million, down 1.7%; organic down 1.6%, driven by the United States, with declines in body wash, underarm protection and toothpaste. Operating profit fell 11% to $177 million, and margin fell 210 bps to 19.5%. Higher SG&A, mostly advertising, took 160 bps, and lower gross margin took 70 bps; within gross margin, material costs rose 520 bps against 350 bps of savings.
- Latin America: $1,326 million, up 12.5% including 6.5% currency; organic up 6.0%, led by Brazil, Argentina and Colombia. Operating profit rose 17% to $392 million.
- EMEA: $1,130 million, up 1.4%; organic up 2.7%, led by Türkiye, the United Kingdom and Spain and partly offset by the Middle East region. Operating profit rose 8% to $262 million.
- Asia Pacific: $802 million, up 3.5%; organic up 4.6%, led by India, Greater China and the Philippines. Operating profit slipped 1% to $211 million, and margin fell 110 bps to 26.4%. Higher advertising was one cause; the other was material costs, up 550 bps and only partly offset by 380 bps of savings.
- Hill's Pet Nutrition: $1,205 million, up 5.6%; organic up 5.7%, net of a 70 bp private label drag, on growth in therapeutic and wellness foods. Operating profit rose 5% to $267 million, but margin fell 20 bps to 22.2%. Higher SG&A, driven by a 290 bp rise in advertising as a share of sales, outweighed a 170 bp gross profit gain.
Nine months. Net sales rose 6.0% to $16,055 million, and organic sales grew 3.0%. GAAP operating profit fell 5% to $3,069 million. It absorbed $327 million of restructuring charges, out of $333 million pre-tax for the period, with $300 million recorded in other expense. Excluding those charges, and the ERISA and acquisition costs in the 2025 period, operating profit rose to $3,396 million from $3,240 million. GAAP diluted EPS was $2.61 against $2.67. Excluding the items, EPS rose 7% to $2.94. Management estimates a full-year effective tax rate of 23.5% before discrete items.
Restructuring expanded. On April 30, 2026 the Board expanded the Strategic Growth and Productivity Program. Expected total pre-tax charges rose to $350–$550 million from $200–$300 million. Annualized pre-tax savings are projected at $200–$300 million, and substantially all charges are expected by December 31, 2028. About 70–80% of the charges are employee-related, and EMEA accounts for the largest share (25–30%). Cumulative charges reached $346 million pre-tax ($278 million after tax) by September 30, 2026, and the restructuring accrual stood at $172 million.
Cash, debt and capital return. Operating cash flow for the nine months rose 6% to $2,913 million, and capital expenditures were $400 million. Capex is planned at about 3.0% of 2026 net sales. In Q1 2026 Colgate repaid at maturity $500 million of 4.800% notes and €500 million of 0.500% notes, funding both with commercial paper. Commercial paper rose to $1,037 million from $147 million at year-end, while total debt fell to $7,716 million from $7,988 million. Cash was $1,527 million, of which $1,515 million was held abroad. Dividends paid in the nine months were $1,308 million; the quarterly dividend rose to $0.53 from $0.52 starting in Q2. Share repurchases cost $927 million. In Q3 alone the company bought about 3.68 million shares at an average $89.70, leaving about $3,228 million under the 2025 Program.
Full-year 2026 guidance (October 30, 2026, at spot rates). The company raised its margin and Base Business EPS outlook and narrowed the sales range:
- Net sales up 4% to 5% (previously 2% to 6%), including a low-single-digit currency benefit.
- Organic sales growth broadly in line with the nine-month rate (previously 1% to 4%), including the effect of exiting private label pet food.
- Gross margin up on both a GAAP and Base Business basis (previously roughly flat). Advertising up in dollars and as a percentage of sales.
- GAAP EPS up by a double-digit percentage.
- Base Business EPS up 5% to 7% (previously mid-single digits).
Outlook risks management flags. Management expects category softness to last through the rest of 2026. It also expects continued pressure from tariffs and USMCA renegotiation, the Ukraine war, and the Middle East conflict's effect on oil, resin and freight costs. In management's view, consumers may trade down or switch to private label.
Litigation update.
- Talc: 561 individual cases were pending at September 30, 2026, against 525 at June 30. In the nine months, 236 new cases were filed and 128 resolved, and settlements were not material. The 10-K had reported 454 pending cases at December 31, 2025, up from 308 a year earlier; the 10-Q gives the year-end figure as 453.
- ERISA: the pension lawsuit was settled for $332 million, inclusive of fees. The court granted final approval in January 2026, and the $99 million of plaintiffs' attorneys' fees has been paid by the company.
- Overall exposure: Colgate estimates reasonably possible losses above accruals at $0 to about $225 million across disclosed matters.
Subsequent events
From the Q3 2026 Form 10-Q, accession 0000021665-26-000048, and Form 8-K accession 0000021665-26-000047.
The Q3 2026 10-Q has no separate subsequent-events note. It reports no acquisitions, divestitures, debt issuances or other financings after September 30, 2026. Post-quarter developments in the filings:
- Brazilian tax litigation (October 2026). This case stems from Colgate's 1995 purchase of the Kolynos oral care business. In December 2025, the Brazilian Federal Court of Appeals ruled against the company on deducting corporate income tax for 1999–2001, a case worth about $19 million. Colgate's further appeals were denied in August and again in October 2026, and it has appealed again. The disputed interest-deduction assessments that include this case total about $107 million at current exchange rates. Colgate believes it is more likely than not to prevail.
- Guidance raised (October 30, 2026). The Q3 earnings release raised full-year 2026 guidance, as detailed above.
AI synthesis of events in 16 filings
Filings that contain financial statements
Each earnings 8-K below furnishes a press release (Exhibit 99) with condensed unaudited statements. These are not the audited or reviewed filings; the Form 10-Q and Form 10-K carry the full statements.
- Form 8-K filed 2026-10-30, accession 0000021665-26-000047: third quarter 2026 results. Income statements for the three and nine months ended September 30, 2026 and 2025; balance sheets at September 30, 2026, December 31, 2025 and September 30, 2025; nine-month cash flow statements for 2026 and 2025; segment information and non-GAAP reconciliations.
- Form 8-K filed 2026-07-31, accession 0000021665-26-000041: second quarter 2026 results (three and six months ended June 30, 2026 and 2025), with condensed income statements, balance sheets, six-month cash flows and segment tables.
- Form 8-K filed 2026-05-01, accession 0000021665-26-000022: first quarter 2026 results (three months ended March 31, 2026 and 2025), with the same set of condensed statements.
- Form 8-K filed 2026-03-17, accession 0000021665-26-000010: recast segment information (no consolidated statements) for 2025, 2024 and 2023 and for the 2025 interim periods, on the new segment structure.
- Form 8-K filed 2026-01-30, accession 0000021665-26-000003: fourth quarter and full year 2025 results (year ended December 31, 2025 and 2024).
Earnings and guidance
- 2026-10-30 (0000021665-26-000047): Third quarter 2026 net sales were $5,369 million, up 4.6% from $5,131 million. Organic sales rose 3.6%, which includes a 0.2% drag from lower private label pet food sales. GAAP diluted EPS was $0.94 against $0.91, and Base Business (non-GAAP) EPS was $0.97, up 7%. GAAP gross margin was 60.2%, up 80 basis points. Net cash from operations was $2,913 million for the first nine months of 2026, against $2,745 million a year earlier. The company narrowed its sales guidance and raised gross margin and Base Business EPS guidance for full-year 2026:
- Net sales are now expected up 4% to 5% (previously 2% to 6%).
- Organic sales growth is now expected broadly in line with the nine-month performance (previously 1% to 4%).
- GAAP and Base Business gross margin are now expected up (previously roughly flat).
- Base Business EPS growth is now expected at 5% to 7% (previously mid-single-digit).
- Advertising is still expected up in dollars and as a share of sales, and GAAP EPS is still expected to grow by double digits.
- 2026-07-31 (0000021665-26-000041): Second quarter 2026 net sales rose 4.9% and organic sales rose 2.4%. GAAP EPS fell 5% to $0.86 and Base Business EPS rose 8% to $0.99. Guidance for sales and GAAP EPS was maintained. GAAP and Base Business gross margin guidance moved to roughly flat (previously down), and Base Business EPS growth to mid-single-digit (previously low- to mid-single-digit).
- 2026-05-01 (0000021665-26-000022): First quarter 2026 net sales rose 8.4% and organic sales rose 2.9%. GAAP EPS fell 6% to $0.80 and Base Business EPS rose 7% to $0.97. Sales and EPS guidance was maintained. Gross margin guidance moved to down (previously up).
- 2026-01-30 (0000021665-26-000003): Full-year 2025 net sales were $20,382 million, up 1.4%. GAAP EPS fell 25% to $2.63, reflecting the skin health impairment below. Base Business EPS rose 3% to $3.69, and operating cash flow was a record $4,198 million. Initial 2026 guidance was net sales up 2% to 6%, organic growth of 1% to 4%, gross margin expansion, and low to mid-single-digit Base Business EPS growth.
- 2025-10-31 (0000021665-25-000052): Third quarter 2025 net sales rose 2.0%, organic sales rose 0.4%, and GAAP EPS was $0.91. The company updated its organic sales guidance for 2025 and maintained its EPS guidance.
Impairment
- Fourth quarter 2025, reported 2026-01-30 (0000021665-26-000003): the company took a non-cash, after-tax charge of $794 million to adjust the carrying values of goodwill and intangible assets of the skin health business. It cited lower than expected category growth and weaker performance, particularly in China, and lowered its outlook for the business, primarily Filorga. Goodwill on the balance sheet fell from $3,702 million at September 30, 2025 to $3,122 million at December 31, 2025 (0000021665-26-000047, Table 3).
Restructuring: Strategic Growth and Productivity Program
- 2025-07-31 (0000021665-25-000040): the Board approved a three-year productivity program with expected cumulative pre-tax charges of $200 to $300 million, substantially all incurred by December 31, 2028, recorded in the Corporate segment.
- 2025-10-31 (0000021665-25-000052): the program was named the Strategic Growth and Productivity Program. Charges were estimated at 65% to 75% employee-related and 25% to 35% asset-related and other, with 75% to 85% resulting in cash.
- 2026-05-01 (0000021665-26-000022): on April 30, 2026 the Board approved an expansion. Cumulative pre-tax charges are now estimated at $350 million to $550 million (previously $200 million to $300 million). The mix is 70% to 80% employee-related and 20% to 30% asset-related and other, with 80% to 90% in cash. Substantially all charges are still expected by December 31, 2028. By region the charges are North America 5% to 10%, Latin America 15% to 20%, Europe, Middle East & Africa 25% to 30%, Asia Pacific 10% to 15%, Hill's Pet Nutrition 10% to 15% and Corporate 20% to 25%.
- The Form 10-Q for the quarter ended September 30, 2026 (accession 0000021665-26-000048) states that Corporate operating profit for the nine months included program charges of $327 million.
Segment realignment
- 2026-03-17 (0000021665-26-000010): effective for the quarter ended March 31, 2026, Colgate combined its Europe and Africa/Eurasia (excluding Russia and Belarus) segments and its Skin Health business (previously in North America) into a new Europe, Middle East & Africa segment. Russia and Belarus moved from Africa/Eurasia to Asia Pacific. Consolidated results were unchanged. The exhibit recasts segment sales and operating profit for 2023, 2024 and 2025 and for the 2025 interim periods.
- Basis note: the Form 10-K for 2025 (accession 0000021665-26-000006) reports segments on the former structure. The Form 10-Q and the 2026 earnings releases use the new structure, and their 2025 comparatives are recast. Segment figures from the 2025 filings and 2026 filings should not be compared without the recast exhibit. As an example of the new basis, the recast 2025 full-year net sales were $4,276 million for Europe, Middle East & Africa and $3,679 million for North America.
Capital actions
- 2025-05-02 (0001104659-25-044105): $500 million of 4.200% Senior Notes due 2030 were issued on May 2, 2025 (underwriting agreement April 28, 2025).
- 2025-11-10 (0001104659-25-109135): EUR 600 million of 3.250% Senior Notes due 2035 were issued on November 10, 2025 (underwriting agreement November 3, 2025).
- Share repurchases and dividends: for the first nine months of 2026, purchases of treasury shares were $927 million (against $804 million in 2025) and dividends paid were $1,308 million (against $1,300 million), per the cash flow statement in 0000021665-26-000047. The 10-Q shows dividends of $0.53 per share in the third quarter of 2026, against $0.52.
- Total debt was $7,716 million at September 30, 2026, against $7,988 million at December 31, 2025 (0000021665-26-000047, Table 3).
M&A
- No acquisition or divestiture 8-K appears in the period. The Form 10-Q (0000021665-26-000048, Note 4) describes a completed acquisition: on April 30, 2025 the company acquired Care TopCo Pty Ltd, owner of the Prime100 fresh pet food business in Australia, for cash consideration of AU$471 million ($301 million), financed with debt and cash. It is closed, and was disclosed in the 10-Q rather than in an 8-K.
Management and board
- 2025-05-29 (0000021665-25-000025): Shane Grant (formerly of Danone) was elected Chief Operating Officer, Americas, effective June 16, 2025. Prabha Parameswaran, Group President, Growth and Strategy, announced her retirement effective October 1, 2025 and became Vice Chair. Panagiotis Tsourapas and John Hazlin were promoted.
- 2026-03-12 (0000021665-26-000008): Christopher S. Boerner (Chair and CEO of Bristol Myers Squibb) was elected to the Board effective March 15, 2026. Steven Cahillane, who became CEO of Kraft Heinz, said he would not stand for re-election in May 2026.
- 2026-04-09 (0000021665-26-000015): Chief Legal Officer and Secretary Jennifer Daniels will retire in 2026. Betsy Fishbone becomes Chief Legal Officer and Secretary on June 1, 2026, and Ms. Daniels becomes Vice Chair.
- 2026-05-13 (0000021665-26-000025): at the May 8, 2026 annual meeting, all ten nominees were elected, auditor PricewaterhouseCoopers was ratified, and the say-on-pay vote passed. Stockholder proposals on removing DEI from board candidate considerations and on an independent Board Chairman were not approved. A similar independent chairman proposal and a plastic packaging proposal also failed at the 2025 meeting (0000021665-25-000022).
Financials
Figures link to the filing they came from. Wherever the SEC filing tags a number, that number is linked: click it and the filing opens at the exact line that prints it. A figure with no link was either derived by AI, such as a margin, free cash flow or a trailing-twelve-month total, or taken from a filing that does not tag its numbers, such as an earnings release.
About this file
| Ticker | CL |
|---|---|
| CIK | 0000021665 |
| Company | Colgate-Palmolive Company |
| Business type | industrial |
| Schema template | consumer products (standard industrial template): net sales, cost of sales, gross profit, SG&A, other (income) expense, operating profit, interest, pre-tax income, income taxes, net income including and attributable to noncontrolling interests, net income attributable to Colgate-Palmolive, basic and diluted EPS with weighted shares; full balance sheet with total debt; operating, investing and financing cash flow, capital expenditures, free cash flow, dividends and share repurchases; dividends declared per share; segment net sales and operating profit; and the company's non-GAAP net income and diluted EPS |
| Reporting currency | USD |
| Converted to USD | no |
| Units | actual US dollars (not millions); per-share amounts in dollars; share counts in actual shares. Cash flow lines carry the sign the cash flow statement prints (outflows negative). |
CL annual income statement, balance sheet and cash flow
Taken from the SEC filings and normalized to actual dollars.
| FY2025 | FY2024 | FY2023 | |
|---|---|---|---|
| Period start | 2025-01-01 | 2024-01-01 | 2023-01-01 |
| Period end | 2025-12-31 | 2024-12-31 | 2023-12-31 |
| Period type | fiscal year | fiscal year | fiscal year |
| Source accession | 10-K | 10-K | 10-K |
| Source form | 10-K | 10-K | 10-K |
| Income statement | |||
| Net sales | 20,382,000,000 | 20,101,000,000 | 19,457,000,000 |
| Cost of sales | 8,131,000,000 | 7,940,000,000 | 8,131,000,000 |
| Gross profit | 12,251,000,000 | 12,161,000,000 | 11,326,000,000 |
| Selling general and administrative expenses | 7,903,000,000 | 7,729,000,000 | 7,151,000,000 |
| Other income expense net | 123,000,000 | 164,000,000 | 191,000,000 |
| Operating profit | 3,306,000,000 | 4,268,000,000 | 3,984,000,000 |
| Non service related postretirement costs | 55,000,000 | 87,000,000 | 360,000,000 |
| Interest expense | 267,000,000 | 292,000,000 | 287,000,000 |
| Interest income | 75,000,000 | 67,000,000 | 55,000,000 |
| Income before income taxes | 3,059,000,000 | 3,956,000,000 | 3,392,000,000 |
| Provision for income taxes | 798,000,000 | 907,000,000 | 937,000,000 |
| Net income including noncontrolling interests | 2,261,000,000 | 3,049,000,000 | 2,455,000,000 |
| Net income attributable to noncontrolling interests | 129,000,000 | 160,000,000 | 155,000,000 |
| Net income | 2,132,000,000 | 2,889,000,000 | 2,300,000,000 |
| Basic EPS | 2.64 | 3.53 | 2.78 |
| Diluted EPS | 2.63 | 3.51 | 2.77 |
| Goodwill and intangible assets impairment charges | 919,000,000 | 0 | 0 |
| Basic shares | 808,700,000 | 819,100,000 | 827,400,000 |
| Diluted shares | 811,100,000 | 823,200,000 | 829,200,000 |
| Dividends declared per share | 2.08 | 2.48 | 1.91 |
| Balance sheet | |||
| Cash and cash equivalents | 1,288,000,000 | 1,096,000,000 | |
| Receivables net | 1,675,000,000 | 1,521,000,000 | |
| Inventories | 2,032,000,000 | 1,987,000,000 | |
| Other current assets | 714,000,000 | 713,000,000 | |
| Total current assets | 5,709,000,000 | 5,317,000,000 | |
| Property plant and equipment net | 4,660,000,000 | 4,422,000,000 | |
| Goodwill | 3,122,000,000 | 3,272,000,000 | |
| Other intangible assets net | 1,536,000,000 | 1,756,000,000 | |
| Deferred income tax assets | 205,000,000 | 195,000,000 | |
| Other assets | 1,098,000,000 | 1,084,000,000 | |
| Total assets | 16,330,000,000 | 16,046,000,000 | |
| Debt payable within one year | 1,117,000,000 | 660,000,000 | |
| Accounts payable | 2,089,000,000 | 1,805,000,000 | |
| Accrued income taxes | 383,000,000 | 403,000,000 | |
| Other accruals | 3,264,000,000 | 2,891,000,000 | |
| Total current liabilities | 6,853,000,000 | 5,759,000,000 | |
| Long term debt | 6,871,000,000 | 7,289,000,000 | |
| Deferred income tax liabilities | 181,000,000 | 343,000,000 | |
| Other liabilities | 2,060,000,000 | 2,111,000,000 | |
| Total liabilities | 15,965,000,000 | 15,502,000,000 | |
| Common stock | 1,466,000,000 | 1,466,000,000 | |
| Additional paid in capital | 4,322,000,000 | 4,181,000,000 | |
| Retained earnings | 26,595,000,000 | 26,145,000,000 | |
| Accumulated other comprehensive loss | -3,879,000,000 | -4,222,000,000 | |
| Treasury stock at cost | -28,450,000,000 | -27,358,000,000 | |
| Total colgate palmolive shareholders equity | 54,000,000 | 212,000,000 | |
| Noncontrolling interests | 311,000,000 | 332,000,000 | |
| Total equity | 365,000,000 | 544,000,000 | |
| Total liabilities and equity | 16,330,000,000 | 16,046,000,000 | |
| Total debt | 7,988,000,000 | 7,949,000,000 | |
| Common shares outstanding | 801,239,524 | 812,574,698 | |
| Cash flow | |||
| Depreciation and amortization | 630,000,000 | 605,000,000 | 567,000,000 |
| Stock based compensation expense | 155,000,000 | 135,000,000 | 122,000,000 |
| Operating cash flow | 4,198,000,000 | 4,107,000,000 | 3,745,000,000 |
| Capital expenditures | -564,000,000 | -561,000,000 | -705,000,000 |
| Payment for acquisitions net of cash acquired | -293,000,000 | 0 | 0 |
| Investing cash flow | -817,000,000 | -534,000,000 | -742,000,000 |
| Short term borrowing repayment net | -989,000,000 | 93,000,000 | -906,000,000 |
| Principal payments on debt | -655,000,000 | -503,000,000 | -903,000,000 |
| Proceeds from issuance of debt | 1,188,000,000 | 2,000,000 | 1,495,000,000 |
| Dividends paid | -1,823,000,000 | -1,789,000,000 | -1,749,000,000 |
| Purchases of treasury shares | -1,210,000,000 | -1,739,000,000 | -1,128,000,000 |
| Proceeds from exercise of stock options | 101,000,000 | 638,000,000 | 380,000,000 |
| Financing cash flow | -3,256,000,000 | -3,389,000,000 | -2,793,000,000 |
| Cash and cash equivalents end of period | 1,288,000,000 | 1,096,000,000 | 966,000,000 |
| Income taxes paid | 913,000,000 | 933,000,000 | 937,000,000 |
| Interest paid | 270,000,000 | 302,000,000 | 280,000,000 |
| Free cash flow | 3,634,000,000 | 3,546,000,000 | 3,040,000,000 |
| Segments | |||
| Source accession | 10-K | 10-K | 10-K |
| North america | |||
| Net sales | 4,045,000,000 | 4,113,000,000 | 4,091,000,000 |
| Operating profit | 784,000,000 | 839,000,000 | 871,000,000 |
| Latin america | |||
| Net sales | 4,776,000,000 | 4,782,000,000 | 4,640,000,000 |
| Operating profit | 1,411,000,000 | 1,526,000,000 | 1,417,000,000 |
| Europe | |||
| Net sales | 2,962,000,000 | 2,770,000,000 | 2,571,000,000 |
| Operating profit | 748,000,000 | 658,000,000 | 573,000,000 |
| Asia pacific | |||
| Net sales | 2,814,000,000 | 2,858,000,000 | 2,782,000,000 |
| Operating profit | 760,000,000 | 812,000,000 | 767,000,000 |
| Africa eurasia | |||
| Net sales | 1,172,000,000 | 1,095,000,000 | 1,083,000,000 |
| Operating profit | 255,000,000 | 253,000,000 | 254,000,000 |
| Pet nutrition | |||
| Net sales | 4,613,000,000 | 4,483,000,000 | 4,290,000,000 |
| Operating profit | 1,064,000,000 | 965,000,000 | 806,000,000 |
| Total oral personal and home care | |||
| Net sales | 15,769,000,000 | 15,618,000,000 | 15,167,000,000 |
| Operating profit | 3,959,000,000 | 4,088,000,000 | 3,882,000,000 |
| Corporate | |||
| Operating profit | -1,717,000,000 | -784,000,000 | -704,000,000 |
| Total | |||
| Net sales | 20,382,000,000 | 20,101,000,000 | 19,457,000,000 |
| Operating profit | 3,306,000,000 | 4,268,000,000 | 3,984,000,000 |
| Segments recast to 2026 structure | |||
| Source accession | 0000021665-26-000010 | 0000021665-26-000010 | 0000021665-26-000010 |
| North america | |||
| Net sales | 3,679,000,000 | 3,716,000,000 | 3,665,000,000 |
| Operating profit | 790,000,000 | 856,000,000 | 834,000,000 |
| Latin america | |||
| Net sales | 4,776,000,000 | 4,782,000,000 | 4,640,000,000 |
| Operating profit | 1,411,000,000 | 1,526,000,000 | 1,417,000,000 |
| Europe middle east and africa | |||
| Net sales | 4,276,000,000 | 4,046,000,000 | 3,822,000,000 |
| Operating profit | 938,000,000 | 814,000,000 | 754,000,000 |
| Asia pacific | |||
| Net sales | 3,038,000,000 | 3,074,000,000 | 3,041,000,000 |
| Operating profit | 820,000,000 | 892,000,000 | 878,000,000 |
| Pet nutrition | |||
| Net sales | 4,613,000,000 | 4,483,000,000 | 4,290,000,000 |
| Operating profit | 1,064,000,000 | 965,000,000 | 806,000,000 |
| Total oral personal and home care | |||
| Net sales | 15,769,000,000 | 15,618,000,000 | 15,167,000,000 |
| Operating profit | 3,959,000,000 | 4,088,000,000 | 3,882,000,000 |
| Corporate | |||
| Operating profit | -1,717,000,000 | -784,000,000 | -704,000,000 |
| Total | |||
| Net sales | 20,382,000,000 | 20,101,000,000 | 19,457,000,000 |
| Operating profit | 3,306,000,000 | 4,268,000,000 | 3,984,000,000 |
| Non GAAP | |||
| Adjusted income before income taxes | 4,065,000,000 | 4,041,000,000 | |
| Adjusted net income | 2,996,000,000 | 2,962,000,000 | |
| Adjusted diluted EPS | 3.69 | 3.60 | |
| Adjustments to net income | |||
| Goodwill and intangible assets impairment charges | 794,000,000 | ||
| Erisa litigation matter | 53,000,000 | ||
| Restructuring programs | 11,000,000 | 73,000,000 | |
| Acquisition related costs | 7,000,000 | ||
- Segments: basis. Five geographic Oral, Personal and Home Care segments (North America, Latin America, Europe, Asia Pacific, Africa/Eurasia) plus Pet Nutrition, as reported in the FY2025 10-K, before the realignment effective for the quarter ended March 31, 2026. Not comparable segment-by-segment with the 2026 quarterly figures; product-segment totals (Oral, Personal and Home Care; Pet Nutrition) and Corporate are unaffected.
- Segments: note. Segment net sales and operating profit as reported. Operating profit for each operating segment excludes Corporate items (stock-based compensation, research and development, Corporate overhead, restructuring charges and, in 2025, the goodwill and intangible assets impairment charges), which are shown on the Corporate line.
- Segments recast to 2026 structure: basis. The same fiscal year recast by the company to the four-segment structure effective for the quarter ended March 31, 2026 (North America; Latin America; Europe, Middle East & Africa; Asia Pacific), furnished in the company's Form 8-K of March 17, 2026 (accession 0000021665-26-000010). Unaudited. Directly comparable with the 2026 quarterly segment figures.
CL quarterly income statement, balance sheet and cash flow
Taken from the SEC filings and normalized to actual dollars.
| Q3 FY2026 | Q3 FY2025 | |
|---|---|---|
| Fiscal quarter | 3 | 3 |
| Period start | 2026-07-01 | 2025-07-01 |
| Period end | 2026-09-30 | 2025-09-30 |
| Period type | three months | three months |
| Source accession | 10-Q | 10-Q |
| Source form | 10-Q | 10-Q |
| Income statement | ||
| Net sales | 5,369,000,000 | 5,131,000,000 |
| Cost of sales | 2,136,000,000 | 2,082,000,000 |
| Gross profit | 3,233,000,000 | 3,049,000,000 |
| Selling general and administrative expenses | 2,111,000,000 | 1,971,000,000 |
| Other income expense net | 34,000,000 | 19,000,000 |
| Operating profit | 1,088,000,000 | 1,059,000,000 |
| Non service related postretirement costs | 24,000,000 | 21,000,000 |
| Interest expense | 62,000,000 | 67,000,000 |
| Interest income | 17,000,000 | 21,000,000 |
| Income before income taxes | 1,019,000,000 | 992,000,000 |
| Provision for income taxes | 240,000,000 | 226,000,000 |
| Net income including noncontrolling interests | 779,000,000 | 766,000,000 |
| Net income attributable to noncontrolling interests | 28,000,000 | 31,000,000 |
| Net income | 751,000,000 | 735,000,000 |
| Basic EPS | 0.94 | 0.91 |
| Diluted EPS | 0.94 | 0.91 |
| Basic shares | 796,900,000 | 807,800,000 |
| Diluted shares | 799,700,000 | 810,200,000 |
| Dividends declared per share | 0.53 | 0.52 |
| Balance sheet | ||
| Cash and cash equivalents | 1,527,000,000 | |
| Receivables net | 1,901,000,000 | |
| Inventories | 2,182,000,000 | |
| Other current assets | 747,000,000 | |
| Total current assets | 6,357,000,000 | |
| Property plant and equipment net | 4,613,000,000 | |
| Goodwill | 3,080,000,000 | |
| Other intangible assets net | 1,472,000,000 | |
| Deferred income tax assets | 222,000,000 | |
| Other assets | 998,000,000 | |
| Total assets | 16,742,000,000 | |
| Debt payable within one year | 532,000,000 | |
| Accounts payable | 2,096,000,000 | |
| Accrued income taxes | 358,000,000 | |
| Other accruals | 3,653,000,000 | |
| Total current liabilities | 6,639,000,000 | |
| Long term debt | 7,184,000,000 | |
| Deferred income tax liabilities | 262,000,000 | |
| Other liabilities | 2,017,000,000 | |
| Total liabilities | 16,102,000,000 | |
| Common stock | 1,466,000,000 | |
| Additional paid in capital | 4,474,000,000 | |
| Retained earnings | 27,415,000,000 | |
| Accumulated other comprehensive loss | -3,866,000,000 | |
| Treasury stock at cost | -29,201,000,000 | |
| Total colgate palmolive shareholders equity | 288,000,000 | |
| Noncontrolling interests | 352,000,000 | |
| Total equity | 640,000,000 | |
| Total liabilities and equity | 16,742,000,000 | |
| Total debt | 7,716,000,000 | |
| Common shares outstanding | 794,920,513 | |
| Cash flow | ||
| Capital expenditures | -134,000,000 | -155,000,000 |
| Depreciation and amortization | 159,000,000 | 158,000,000 |
| Segments | ||
| Source accession | 10-Q | 10-Q |
| North america | ||
| Net sales | 905,000,000 | 922,000,000 |
| Operating profit | 177,000,000 | 199,000,000 |
| Latin america | ||
| Net sales | 1,326,000,000 | 1,178,000,000 |
| Operating profit | 392,000,000 | 337,000,000 |
| Europe middle east and africa | ||
| Net sales | 1,130,000,000 | 1,115,000,000 |
| Operating profit | 262,000,000 | 243,000,000 |
| Asia pacific | ||
| Net sales | 802,000,000 | 775,000,000 |
| Operating profit | 211,000,000 | 213,000,000 |
| Pet nutrition | ||
| Net sales | 1,205,000,000 | 1,142,000,000 |
| Operating profit | 267,000,000 | 255,000,000 |
| Total oral personal and home care | ||
| Net sales | 4,164,000,000 | 3,989,000,000 |
| Operating profit | 1,042,000,000 | 992,000,000 |
| Corporate | ||
| Operating profit | -221,000,000 | -189,000,000 |
| Total | ||
| Net sales | 5,369,000,000 | 5,131,000,000 |
| Operating profit | 1,088,000,000 | 1,059,000,000 |
| Non GAAP | ||
| Adjusted income before income taxes | 1,049,000,000 | 992,000,000 |
| Adjusted net income | 777,000,000 | 735,000,000 |
| Adjusted diluted EPS | 0.97 | 0.91 |
| Adjustments to net income | ||
| Strategic growth and productivity program | 26,000,000 | |
- Segments: basis. Four geographic Oral, Personal and Home Care segments (North America; Latin America; Europe, Middle East & Africa; Asia Pacific) plus Hill's Pet Nutrition, the structure effective for the quarter ended March 31, 2026; the Q3 2026 10-Q recasts 2025 comparatives to this structure.
- Segments: note. Segment net sales and operating profit as reported. Operating profit for each operating segment excludes Corporate items (stock-based compensation, research and development, Corporate overhead, restructuring charges and, in 2025, the goodwill and intangible assets impairment charges), which are shown on the Corporate line.
CL year-to-date income statement and cash flow
Taken from the SEC filings and normalized to actual dollars.
| 9M FY2026 | 9M FY2025 | |
|---|---|---|
| Period start | 2026-01-01 | 2025-01-01 |
| Period end | 2026-09-30 | 2025-09-30 |
| Period type | nine months | nine months |
| Source accession | 10-Q | 10-Q |
| Source form | 10-Q | 10-Q |
| Income statement | ||
| Net sales | 16,055,000,000 | 15,152,000,000 |
| Cost of sales | 6,300,000,000 | 6,047,000,000 |
| Gross profit | 9,755,000,000 | 9,105,000,000 |
| Selling general and administrative expenses | 6,316,000,000 | 5,833,000,000 |
| Other income expense net | 370,000,000 | 58,000,000 |
| Operating profit | 3,069,000,000 | 3,214,000,000 |
| Non service related postretirement costs | 70,000,000 | 116,000,000 |
| Interest expense | 186,000,000 | 203,000,000 |
| Interest income | 50,000,000 | 56,000,000 |
| Income before income taxes | 2,863,000,000 | 2,951,000,000 |
| Provision for income taxes | 682,000,000 | 685,000,000 |
| Net income including noncontrolling interests | 2,181,000,000 | 2,266,000,000 |
| Net income attributable to noncontrolling interests | 91,000,000 | 97,000,000 |
| Net income | 2,090,000,000 | 2,169,000,000 |
| Basic EPS | 2.61 | 2.68 |
| Diluted EPS | 2.61 | 2.67 |
| Basic shares | 799,500,000 | 810,000,000 |
| Diluted shares | 802,200,000 | 812,800,000 |
| Dividends declared per share | 1.59 | 1.56 |
| Cash flow | ||
| Depreciation and amortization | 470,000,000 | 457,000,000 |
| Stock based compensation expense | 141,000,000 | 127,000,000 |
| Operating cash flow | 2,913,000,000 | 2,745,000,000 |
| Capital expenditures | -400,000,000 | -387,000,000 |
| Payment for acquisitions net of cash acquired | 0 | -293,000,000 |
| Investing cash flow | -381,000,000 | -714,000,000 |
| Short term borrowing repayment net | 947,000,000 | 139,000,000 |
| Principal payments on debt | -1,087,000,000 | -655,000,000 |
| Proceeds from issuance of debt | 0 | 497,000,000 |
| Dividends paid | -1,308,000,000 | -1,300,000,000 |
| Purchases of treasury shares | -927,000,000 | -804,000,000 |
| Proceeds from exercise of stock options | 178,000,000 | 83,000,000 |
| Financing cash flow | -2,272,000,000 | -1,895,000,000 |
| Cash and cash equivalents end of period | 1,527,000,000 | 1,279,000,000 |
| Income taxes paid | 648,000,000 | 712,000,000 |
| Interest paid | 205,000,000 | 235,000,000 |
| Free cash flow | 2,513,000,000 | 2,358,000,000 |
| Segments | ||
| Source accession | 10-Q | 10-Q |
| North america | ||
| Net sales | 2,684,000,000 | 2,745,000,000 |
| Operating profit | 510,000,000 | 583,000,000 |
| Latin america | ||
| Net sales | 4,011,000,000 | 3,528,000,000 |
| Operating profit | 1,211,000,000 | 1,052,000,000 |
| Europe middle east and africa | ||
| Net sales | 3,377,000,000 | 3,204,000,000 |
| Operating profit | 791,000,000 | 706,000,000 |
| Asia pacific | ||
| Net sales | 2,388,000,000 | 2,259,000,000 |
| Operating profit | 643,000,000 | 620,000,000 |
| Pet nutrition | ||
| Net sales | 3,594,000,000 | 3,417,000,000 |
| Operating profit | 816,000,000 | 778,000,000 |
| Total oral personal and home care | ||
| Net sales | 12,461,000,000 | 11,735,000,000 |
| Operating profit | 3,155,000,000 | 2,961,000,000 |
| Corporate | ||
| Operating profit | -902,000,000 | -523,000,000 |
| Total | ||
| Net sales | 16,055,000,000 | 15,152,000,000 |
| Operating profit | 3,069,000,000 | 3,214,000,000 |
| Non GAAP | ||
| Adjusted income before income taxes | 3,196,000,000 | 3,027,000,000 |
| Adjusted net income | 2,359,000,000 | 2,228,000,000 |
| Adjusted diluted EPS | 2.94 | 2.74 |
| Adjustments to net income | ||
| Strategic growth and productivity program | 268,000,000 | |
| Erisa litigation matter | 53,000,000 | |
| Acquisition related costs | 7,000,000 | |
- Segments: basis. Four geographic Oral, Personal and Home Care segments (North America; Latin America; Europe, Middle East & Africa; Asia Pacific) plus Hill's Pet Nutrition, the structure effective for the quarter ended March 31, 2026; the Q3 2026 10-Q recasts 2025 comparatives to this structure.
- Segments: note. Segment net sales and operating profit as reported. Operating profit for each operating segment excludes Corporate items (stock-based compensation, research and development, Corporate overhead, restructuring charges and, in 2025, the goodwill and intangible assets impairment charges), which are shown on the Corporate line.
CL trailing twelve month income statement and cash flow
Derived by AI from the figures the filings report. No filing prints these, so none of them is linked.
| TTM ended September 30, 2026 | |
|---|---|
| Period start | 2025-10-01 |
| Period end | 2026-09-30 |
| Period type | trailing twelve months |
| Source accession | 10-Q |
| Source accessions | 10-K, 10-Q |
| Income statement | |
| Net sales | 21,285,000,000 |
| Cost of sales | 8,384,000,000 |
| Gross profit | 12,901,000,000 |
| Selling general and administrative expenses | 8,386,000,000 |
| Other income expense net | 435,000,000 |
| Operating profit | 3,161,000,000 |
| Income before income taxes | 2,971,000,000 |
| Provision for income taxes | 795,000,000 |
| Net income including noncontrolling interests | 2,176,000,000 |
| Net income | 2,053,000,000 |
| Goodwill and intangible assets impairment charges | 919,000,000 |
| Cash flow | |
| Operating cash flow | 4,366,000,000 |
| Capital expenditures | -577,000,000 |
| Dividends paid | -1,831,000,000 |
| Purchases of treasury shares | -1,333,000,000 |
| Free cash flow | 3,789,000,000 |
- Derivation. FY2025 (FY2025 10-K) plus the nine months ended September 30, 2026, less the nine months ended September 30, 2025 (both from the Q3 2026 10-Q).
Adjustments
| Splits applied | none |
|---|---|
| ADR ratio | n/a |
| FX | none; Colgate-Palmolive reports in US dollars |
Notes
- Sources: annual figures for 2025, 2024 and 2023 are from the FY2025 Form 10-K (accession 0000021665-26-000006); quarterly, nine-month and September 30, 2026 balance sheet figures are from the Q3 2026 Form 10-Q (accession 0000021665-26-000048). The 10-K prints balance sheets for December 31, 2025 and 2024 only, so FY2023 carries no balance sheet.
- net_income is net income attributable to Colgate-Palmolive Company, the figure earnings per share are based on; net income including the share attributable to noncontrolling interests is reported separately.
- Weighted basic and diluted share counts are from the earnings per share notes (Note 12 of the 10-K, Note 7 of the 10-Q), printed there in millions. common_shares_outstanding is the count of common shares outstanding: at December 31, 2025 and 2024 from the 10-K's share activity table, and at September 30, 2026 from the 10-Q cover page.
- total_debt is debt payable within one year plus long-term debt as printed on the balance sheet. free_cash_flow is net cash provided by operations less capital expenditures; the company calls this 'free cash flow before dividends' and its Q3 2026 earnings release (Form 8-K, accession 0000021665-26-000047) reports free cash flow before dividends of $2,513 million and $2,358 million for the nine months of 2026 and 2025.
- The 10-Q presents its cash flow statement for the nine-month periods only, so the three-month quarters carry no operating cash flow or free cash flow. Their capital expenditures and depreciation and amortization are the totals of the 10-Q's segment note, which prints the three-month figures; capital expenditures are shown as outflows to match the cash flow statement's sign.
- Dividends declared per share are from the statements of changes in shareholders' equity. The 10-K notes that five dividends were declared in 2024 and four in each of 2025 and 2023, which is why the 2024 per-share figure ($2.48) is higher than 2025's ($2.08).
- 2025 operating profit and net income include $919 million of goodwill and intangible assets impairment charges (recorded in Corporate). The nine months of 2026 include $327 million of Strategic Growth and Productivity Program charges in Corporate operating profit ($29 million in the third quarter), most of it in Other (income) expense, net.
- Segments: effective for the quarter ended March 31, 2026 the company realigned its geographic reporting, combining Europe, Africa/Eurasia (excluding Russia and Belarus) and the skin health business (previously in North America) into a new Europe, Middle East & Africa segment, and moving Russia and Belarus into Asia Pacific. Quarterly and nine-month segment figures are on the new four-segment basis, with 2025 comparatives recast by the company in the 10-Q. Each annual period carries two segment views, each labelled with its basis: 'segments' as the FY2025 10-K reported them (five geographic segments), and 'segments_recast_to_2026_structure' from the company's recast furnished on Form 8-K on March 17, 2026 (accession 0000021665-26-000010). Consolidated results, product-segment totals and Corporate are identical in both views; the realignment changed no consolidated figure.
- non_gaap figures are the company's own reconciliations in the 10-K and 10-Q MD&A, which exclude the items listed (impairment, ERISA litigation, restructuring, acquisition-related costs, Strategic Growth and Productivity Program charges). The 10-Q shows no adjustments for the third quarter of 2025, so its non-GAAP figures equal GAAP. The 10-K's reconciliation covers 2025 and 2024 only.
- The trailing-twelve-month view is derived: FY2025 plus the nine months of 2026 less the nine months of 2025. It includes the fourth quarter of 2025, which carried the full $919 million impairment charge (the 2025 nine-month income statement shows none). Per-share figures are not derived for it because the company computes earnings per share independently for each period.
Uncertainties
- Three-month operating cash flow and free cash flow for the third quarters of 2026 and 2025 are not reported: the 10-Q prints cash flows for the nine-month periods only.
- The recast annual segment figures come from an unaudited exhibit furnished on Form 8-K, not from the audited 10-K.
Company details
| Name | Colgate Palmolive Co |
|---|---|
| Ticker | CL |
| CIK | 0000021665 |
| Exchange | NYSE |
| State | New York |
| Incorporation | Delaware |
| SIC | 2844 |
| Office | Industrial Applications and Services |
| Industry | Perfumes, Cosmetics & Other Toilet Preparations |
Fiscal period
| Fiscal year | 2026 |
|---|---|
| Fiscal period | Q3 |
| Tag | FY26Q3 |
| Period end | 2026-09-30 |
| Form | 10-Q |
| Accession | 0000021665-26-000048 |
| Fiscal year end | 1231 |
| Source | facts |
Source filings
| Role | Current | Form | Fiscal year | Fiscal period | Tag | Period end | Filed | Accession | Source |
|---|---|---|---|---|---|---|---|---|---|
| annual | no | 10-K | 2025 | FY | FY25 | 2025-12-31 | 2026-02-23 | 0000021665-26-000006 | reported |
| quarterly | yes | 10-Q | 2026 | Q3 | FY26Q3 | 2026-09-30 | 2026-10-30 | 0000021665-26-000048 | facts |